BioSig Technologies, Inc. — FY2017 Form 10-K
Entity note: The request identifies Streamex Corp., but the supplied filing is for BioSig Technologies, Inc. This summary reflects the filing. It covers the fiscal year ended December 31, 2017, with 2016 comparative results; it is not a standalone fourth-quarter report.
Business context
BioSig is a development-stage medical-device company developing the PURE EP System, an electrocardiogram and intracardiac recording and analysis system for electrophysiology procedures. The company had no commercial products, customers, or revenue in 2017. It reported progress toward commercialization, including receipt of initial production units from manufacturing partner Minnetronix, but still required FDA 510(k) clearance.
Financial results and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue and cost of goods sold | $0 | $0 |
| Research and development expense | $4.76 million | $2.65 million |
| General and administrative expense | $8.14 million | $8.50 million |
| Operating loss | $12.91 million | $11.16 million |
| Net loss | $12.70 million | $11.59 million |
| Net loss available to common stockholders | $12.82 million | $11.70 million |
| Basic and diluted loss per share | $0.50 | $0.60 |
| Cash used in operating activities | $7.47 million | $5.11 million |
| Cash at year-end | $1.55 million | $1.06 million |
Gross and operating margins are not meaningful because the company had no revenue. Operating expenses increased 16% overall; R&D rose 79%, primarily from clinical studies, design work, personnel, and a $544,000 noncash charge for a Mayo Foundation license warrant. The net loss increase was 10%. A $210,000 gain from changes in derivative fair values partly offset operating losses; 2016 had a $423,000 loss on those changes.
At December 31, 2017, current assets were $1.66 million and current liabilities were $3.97 million, including $2.36 million of warrant liabilities and $686,000 of derivative liabilities. Reported working capital deficit was $2.30 million; excluding those warrant and derivative liabilities, it would have been positive $744,000. Stockholders’ deficit was $3.25 million. The filing reports no convertible debentures outstanding, but preferred stock, dividends, warrants, and related covenants create material financing obligations. No debt balance is clearly reported as outstanding.
Financing activities provided $7.97 million in 2017: $6.04 million from common-stock and warrant sales and $1.93 million from Series D preferred stock. Cash used in investing activities was $9,000. The company estimated it needed approximately $5 million beyond then-current cash for the next 12 months.
Material changes, outlook, and risks
- R&D spending increased substantially as development and preclinical work advanced; G&A declined 4%, mainly due to lower equity compensation.
- Management expected FDA 510(k) clearance and commencement of U.S. marketing by the end of 2018, subject principally to financing and regulatory approval. CE Mark submission was planned for 2019. These were targets, not assurances.
- The auditor and management cited substantial doubt about the company’s ability to continue as a going concern. The filing gives differing runway estimates: approximately five months in the risk-factor/MD&A discussion and at least six months in the liquidity note. Additional financing was necessary, with no assurance it could be obtained on acceptable terms.
- After year-end, the company raised $1.50 million through Series E preferred stock and warrants and approximately $270,000 through common stock. These transactions provide financing but add potential dilution and include anti-dilution provisions.
- Effective January 1, 2018, the company adopted ASU 2017-11 and reclassified $3.04 million of warrant and derivative liabilities to equity. This accounting change does not itself provide cash.
- Key risks include development and regulatory failure or delay, limited clinical validation, dependence on future financing and third parties, competition from established device companies, preferred-stock redemption/dividend and covenant terms, and potential dilution from outstanding options, warrants, and convertible preferred stock.
- Management concluded disclosure controls and internal control over financial reporting were ineffective due to a material weakness in segregation of duties; management said full mitigation was impractical and prohibitively costly at the company’s size. The filing also discloses 125 late Form 4 filings relating to approximately 292 transactions by the Executive Chairman and Director.
- The filing reports no material litigation known to the company. The financial statements received an unqualified audit opinion, accompanied by a going-concern emphasis.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is BioSig Technologies, Inc., not Streamex Corp.
- Check subsequent filings for actual FDA submission and clearance timing, production readiness, clinical evidence, and any change to the commercialization schedule.
- Reconcile the stated five- versus six-month cash runway and track cash burn, financing proceeds, and the company’s ability to raise the estimated additional $5 million.
- Review the terms and potential dilution from Series C, D, and E preferred stock, accrued dividends, redemption triggers, warrants, options, and anti-dilution protections.
- Monitor remediation of the material weakness in financial reporting controls and compliance with insider transaction reporting requirements.